−5.68EUR
−189.73 MEUR
238.28 MEUR
35.62 M
About MORPHOSYS AG
Sector
Industry
CEO
Jean-Paul Kress
Website
Headquarters
Planegg
Employees (FY)
564
Founded
1992
ISIN
DE0006632003
FIGI
BBG000C68X01
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MOR is 67.60 EUR — it has increased by 0.07% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange MORPHOSYS AG stocks are traded under the ticker MOR.
MORPHOSYS AG is going to release the next earnings report on Apr 29, 2024. Keep track of upcoming events with our Earnings Calendar.
MOR stock is 0.44% volatile and has beta coefficient of −0.29. Check out the list of the most volatile stocks — is MORPHOSYS AG there?
One year price forecast for MORPHOSYS AG has a max estimate of 68.00 EUR and a min estimate of 40.00 EUR.
MOR earnings for the last quarter are −3.50 EUR per share, whereas the estimation was −2.13 EUR resulting in a −64.22% surprise. The estimated earnings for the next quarter are −1.88 EUR per share. See more details about MORPHOSYS AG earnings.
MORPHOSYS AG revenue for the last quarter amounts to 63.80 M EUR despite the estimated figure of 56.73 M EUR. In the next quarter revenue is expected to reach 59.38 M EUR.
Yes, you can track MORPHOSYS AG financials in yearly and quarterly reports right on TradingView.
MOR stock has risen by 0.22% compared to the previous week, the month change is a 1.87% rise, over the last year MORPHOSYS AG has showed a 260.92% increase.
MOR net income for the last quarter is 48.27 M EUR, while the quarter before that showed −119.60 M EUR of net income which accounts for 140.36% change. Track more MORPHOSYS AG financial stats to get the full picture.
Today MORPHOSYS AG has the market capitalization of 2.55 B, it has decreased by 0.37% over the last week.
No, MOR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MOR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MORPHOSYS AG stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 564.00 employees. See our rating of the largest employees — is MORPHOSYS AG on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MORPHOSYS AG technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MORPHOSYS AG stock shows the buy signal. See more of MORPHOSYS AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MORPHOSYS AG future price: according to them, MOR price has a max estimate of 68.00 EUR and a min estimate of 40.00 EUR. Read a more detailed MORPHOSYS AG forecast: see what analysts think of MORPHOSYS AG and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MORPHOSYS AG EBITDA is −240.32 M EUR, and current EBITDA margin is −95.29%. See more stats in MORPHOSYS AG financial statements.